Digestive diseases (Basel, Switzerland)最新文献

{"title":"Prediction Model of Malignant Risk of Gastrointestinal Stromal Tumor Based on Endoscopic Ultrasonography.","authors":"Kai Lin, Fan Luo, Jie Hou, Rui Huang, Weihui Liu, Shanshan Hu","doi":"10.1159/000551261","DOIUrl":"10.1159/000551261","url":null,"abstract":"<p><p><p>Introduction: Gastrointestinal stromal tumors (GISTs) are clinically heterogeneous mesenchymal tumors, and accurate assessment of their malignancy is crucial for determining treatment strategies and predicting patient prognosis. This study aims to establish and validate a preoperative prediction model for the malignant risk of GIST based on endoscopic ultrasound (EUS) findings.</p><p><strong>Methods: </strong>In this retrospective study, we collected data from patients with GIST at Sichuan Provincial People's Hospital. Statistical analyses involved univariate and multivariate logistic regression models, with Firth's bias reduction penalty likelihood logistic regression employed to address data separation and multicollinearity. Model discrimination was assessed using AUC, and the Bootstrap ROC method was used for validation. Finally, a nomogram was constructed to visually represent the predictive model.</p><p><strong>Results: </strong>In this study, we analyzed 500 patients with GIST, including low (n = 393) and high-risk groups (n = 107). Univariate and multivariate logistic regression analyses revealed hard elastography and contrast-enhanced EUS (CE-EUS) of visible tumor vessels as potent independent risk factors associated with GIST malignancy. Firth's bias reduction penalty likelihood logistic regression confirmed hard elastography (OR = 146.222, 95% CI: 12.597-1,017.552) and CE-EUS with visible tumor vessels (OR = 402.853, 95% CI: 12.732-7,633.787) as significant predictors. Finally, we identified five optimal predictors (including size, shape, echogenicity, elastography, and visible tumor vessels). The predictive model demonstrated exceptional accuracy with an AUC of 0.9998, further validated by bootstrap ROC analysis showing an AUC of 1.</p><p><strong>Conclusion: </strong>A nomogram incorporating tumor size, shape, echogenicity, elastography, and visible tumor vessels was developed. However, because internal validation indicated overfitting, the model's clinical utility requires rigorous external validation. </p>.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"249-259"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Utility of Intestinal Ultrasound for Guiding Therapy in Inflammatory Bowel Disease: A Retrospective Real-World Cohort from a Swiss Tertiary Center.","authors":"Niki Jud, Luc Biedermann, Andrea S Kreienbuehl, Eirini Pagkalidou, Gerhard Rogler, Michael Doulberis","doi":"10.1159/000549554","DOIUrl":"10.1159/000549554","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic immune-mediated disorders that significantly impact patients' quality of life. Proper IBD management often requires invasive diagnostic procedures such as endoscopy. Transabdominal intestinal ultrasound (IUS) offers a promising alternative due to its noninvasive, inexpensive, and widely available nature. This study aimed to evaluate the effectiveness of IUS combined with clinical parameters in guiding treatment decisions for IBD patients in remission or relapse.</p><p><strong>Methods: </strong>This is a retrospective cohort study of University Hospital Zurich (January-August 2022), which included consecutive adult IBD patients undergoing a single transabdominal IUS for treatment decision-making. IUS influenced clinical decisions by guiding therapy continuation, modification, or cessation and addressing complications.</p><p><strong>Results: </strong>The study analyzed 103 consecutive IBD patients, 66% diagnosed with CD, and 34% with UC. The majority (69.9%) were in clinical remission, and two-third of the remission patients claimed also no symptoms (32% of the whole cohort were asymptomatic). Bowel wall thickness (BWT) in the terminal ileum and left colon also significantly influenced treatment decisions (p = 0.014 and p = 0.042, respectively). In a multivariable logistic regression, both diarrhea (p = 0.013) and maximal BWT (p = 0.020) remained statistically significant predictors for a change in treatment.</p><p><strong>Conclusion: </strong>The study demonstrates that IUS, along with clinical symptoms such as diarrhea, plays a significant role in guiding treatment decisions for IBD patients. Diarrhea and BWT were strong predictors for adjusting therapy, highlighting the value of integrating noninvasive imaging with clinical assessment to optimize IBD management.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"42-49"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Diagnostic Journey in Fistulizing Sigmoid Diverticulitis: A Multicenter Retrospective Study and Proposal for a Structured Workup.","authors":"Lennart Zimniak, Joerg-Peter Ritz, Christoph Wullstein, Attila Dubecz, Michael Karg, Kjell Sonnenberg, Hendrik Christian Albrecht, Stephan Gretschel","doi":"10.1159/000549576","DOIUrl":"10.1159/000549576","url":null,"abstract":"<p><p><p>Introduction: Fistulizing sigmoid diverticulitis, most commonly involving colovesical or colovaginal fistulas, is a rare but debilitating complication of chronic diverticular disease. Despite pathognomonic symptoms, diagnostic pathways are often inconsistent, contributing to delayed surgical treatment and increased patient burden. This study examines the preoperative diagnostic pathway of patients with fistulizing diverticulitis in a multicenter cohort in Germany.</p><p><strong>Methods: </strong>In this retrospective study, patients with colovesical, colovaginal, or combined fistulas due to chronic sigmoid diverticulitis who underwent elective sigmoid resection at four tertiary centers between 2012 and 2023 were analyzed. Collected data included clinical symptoms, number and type of diagnostic investigations, time from symptom onset to surgery, and subgroup comparisons.</p><p><strong>Results: </strong>A total number of 101 patients were included in this analysis. The median time from symptom onset to surgery was 8 weeks (IQR 4-16). Recurrent urinary tract infections (78.2%) and pneumaturia (44.6%) were the most frequent symptoms. Patients underwent a median of 4 diagnostic procedures, with CT (90.1%), colonoscopy (81.2%), abdominal ultrasound (80.2%), and cystoscopy (55.4%) being most commonly used. Subgroup analysis revealed a significantly higher number of investigations in patients with surgical delay ≥10 weeks compared to those treated within 6 weeks (median 4 vs. 3; p = 0.0426), while other clinical characteristics did not differ significantly.</p><p><strong>Conclusion: </strong>The diagnostic workup for fistulizing diverticulitis remains heterogeneous and may contribute to treatment delays. Based on our findings, we propose a structured, symptom-guided diagnostic algorithm centered around early recognition, targeted use of high-yield modalities - including colonoscopy, cystoscopy, CT, and the poppy seed test - and prompt referral for surgical treatment. Standardization may improve diagnostic efficiency and reduce patient morbidity. </p>.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"147-155"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12978806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145829812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-Management of Reflux-Like Symptoms: A Patient-Centered Decision-Making Approach.","authors":"A Pali S Hungin, Carmelo Scarpignato, Albert J Bredenoord, Mark R Fox, Elsa López-Pintor, Juan M Mendive, Edoardo Vincenzo Savarino, Peter J Kahrilas","doi":"10.1159/000551414","DOIUrl":"10.1159/000551414","url":null,"abstract":"<p><p><p>Background: Guidelines for the management of reflux-like symptoms (primarily heartburn and regurgitation) offer limited guidance to support decision-making in the nonprescription setting. This review aimed to summarize and compare nonprescription treatment options within the context of reflux-like symptom pathophysiology and provide a practical evidence-based tool to help guide tailored treatment selection. Summary: A patient-centered approach should consider the requirement for reactive versus preventative therapies and each product's unique characteristics. Antacids neutralize refluxed acid in the esophagus, providing temporary relief from occasional heartburn. Raft-forming alginate formulations provide relief of heartburn and regurgitation after meals by forming a viscous gel near the gastroesophageal junction, neutralizing the postprandial acid pocket and coating the esophagus when refluxed. Histamine-2 receptor antagonists reduce gastric acid secretion within 30 min, lasting for up to 12 h, making them useful for treatment and prevention of heartburn, but tachyphylaxis is a limitation. Nonprescription proton pump inhibitors are most effective for preventing frequent acid-related symptoms. They are packaged as a 2-week course for daily use, achieving maximum effect after a few days. Key Messages: Important differences exist among self-management treatment options for reflux-like symptoms. A standardized algorithm is proposed to help tailor treatment selection according to symptom profile. </p>.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"235-248"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13218708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cuproptosis-Related lncRNA Risk Model for Hepatocellular Carcinoma Prognosis and Immunotherapy Response.","authors":"Ziwen Zhuo, Ziwei Guo, HongYe Peng, Xiaoxian Ye, Jiuchong Wang, Wenliang Lv","doi":"10.1159/000548493","DOIUrl":"10.1159/000548493","url":null,"abstract":"<p><strong>Background: </strong>Cuproptosis is a type of cell death caused by copper imbalance associated with the growth and proliferation of cancer cells. Long noncoding RNAs (lncRNAs) play a crucial role in hepatocellular carcinoma (HCC) development. Here, we aimed to investigate the role of cuproptosis-related lncRNAs in the clinical prognostic prediction and immunotherapy for HCC.</p><p><strong>Methods: </strong>A correlation network between lncRNAs and cuproptosis-related genes in HCC was constructed by conducting co-expression and Cox regression analyses. LASSO-Cox analysis was used to obtain lncRNAs that constitute the cuproptosis-associated lncRNA signature, which was then used to predict patient prognosis and immunotherapy response. To verify the clinical applicability of the risk model, a nomogram was constructed and an anti-neoplastic drug sensitivity analysis was performed.</p><p><strong>Results: </strong>Four cuproptosis-related lncRNAs (AL590705.3, SPRY4-AS1, AC135050.5, and AL031985.3) were identified and used to develop a prognostic signature for HCC. Based on the four lncRNAs, a risk prediction model was established. For overall survival (OS) in HCC patients, the area under the ROC curve (AUC) for the risk score was 0.715, outperforming traditional clinical factors such as age (AUC=0.531), gender (AUC=0.509), and stage (AUC=0.671). High-risk patients had worse overall survival, progression-free survival, and higher mortality. Independent ROC analysis, nomogram-based modeling, and concordance index analysis indicated that the risk model has high predictive accuracy for HCC.</p><p><strong>Conclusions: </strong>This model demonstrates potential in predicting prognosis, and offers novel insights to the treatment and management of HCC. Our study suggests that lncRNAs may serve as a novel biomarker and potential therapeutic target for HCC.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1-25"},"PeriodicalIF":2.1,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145461187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Esophageal Baseline Impedance Levels and Reflux Parameters Suggesting Defensive Mechanisms.","authors":"Hye-Su You, Seon-Young Park, Gang Han Lee, Jae Woong Lim, Jin Won Kim, Min Jae Kim, Daesol Kim, Sanghyuk Jung, Yuyeon Kim, Dong Hyun Kim","doi":"10.1159/000546672","DOIUrl":"10.1159/000546672","url":null,"abstract":"<p><strong>Introduction: </strong>Ambulatory multichannel intraluminal impedance-pH (MII-pH) monitoring and high-resolution esophageal manometry (HRM) are commonly performed to objectively assess pathologic reflux and understand the pathomechanism in individuals with reflux symptoms. This study aimed to investigate the relationship between novel MII-pH parameters and other metrics in patients experiencing refractory reflux symptoms.</p><p><strong>Methods: </strong>This retrospective study included patients with persistent reflux symptoms, who underwent both HRM and MII-pH assessments. We evaluated total acid exposure time (AET), bolus clearance time, total number of reflux episodes, post-reflux swallow-induced peristaltic wave index (PSPW-I), and mean nocturnal baseline impedance (MNBI) from MII-pH data. The mean distal contractile integral during swallows was derived from HRM.</p><p><strong>Results: </strong>In this cohort of 55 patients (30 females, median age 58 years), 9 (16.4%) exhibited AET >6.0%, 16 (29.1%) experienced >80 reflux episodes, and 17 (30.9%) had ineffective esophageal motility. Median (10%-90%) MNBI values for Z5 and Z6 were 2,140 (258-4,046) ohms and 1,680 (158-3,994) ohms, respectively. Median PSPW-I (10%-90%) was 0.31 (0.07-0.59). MNBI at Z6 showed negative correlations with AET, bolus clearance time, and total reflux episodes (p < 0.005). Additionally, PSPW-I correlated with MNBI values at Z5 and Z6 (p < 0.005).</p><p><strong>Conclusion: </strong>MNBI is associated with both the quantitative reflux index and defensive parameters against reflux.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"383-390"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Value of Contrast-Enhanced Harmonic Endoscopic Ultrasound in the Diagnosis of Periampullary Mass.","authors":"Shu-Yu Chen, Qiao Qin, Xi Zhou, Ming Zhao, Xiao-Bin Sun, Jing Shan","doi":"10.1159/000548246","DOIUrl":"10.1159/000548246","url":null,"abstract":"<p><strong>Introduction: </strong>Periampullary masses encompass both benign and malignant lesions that are clinically challenging to differentiate. This study aimed to investigate the diagnostic value of contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) for periampullary masses and compare its performance with computed tomography (CT) and magnetic resonance imaging (MRI).</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 54 patients with pathologically confirmed malignant periampullary masses or benign lesions validated by ≥1-year follow-up. Diagnostic efficacy of CH-EUS was evaluated against CT and MRI.</p><p><strong>Results: </strong>All malignant masses exhibited arterial-phase hypo-enhancement, while 78.94% of benign lesions showed iso-enhancement. Venous-phase hypo-enhancement was observed in 94.28% of malignancies, and 57.89% of benign cases demonstrated iso-enhancement. CH-EUS demonstrated superior diagnostic accuracy, sensitivity, specificity, positive predictive value, and negative predictive value compared to CT (all p < 0.05). Its accuracy and sensitivity also exceeded those of MRI (p < 0.05).</p><p><strong>Conclusion: </strong>CH-EUS effectively differentiates benign and malignant periampullary masses, demonstrating high clinical utility.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"697-705"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144986153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Therapeutic Endoscopic Retrograde Cholangiopancreatography in Elderly Patients (≥80 Years) with Choledocholithiasis: A Comprehensive Meta-Analysis.","authors":"Liping Wang, Zhihua Chen","doi":"10.1159/000548378","DOIUrl":"10.1159/000548378","url":null,"abstract":"<p><strong>Introduction: </strong>Endoscopic retrograde cholangiopancreatography (ERCP) is the standard treatment for choledocholithiasis. However, elderly patients, particularly those aged ≥80 and ≥90, may face higher risks of complications due to comorbidities and age-related anatomical changes. This meta-analysis aimed to evaluate the efficacy and safety of ERCP in this population.</p><p><strong>Methods: </strong>A systematic search yielded 17 retrospective studies. Data were synthesized using both single-arm and comparative analyses, with subgroup analyses focusing on nonagenarians (≥90 years). Outcomes assessed included complete stone clearance, cannulation success, adverse events (AEs), sedation strategies, and biliary stent use.</p><p><strong>Results: </strong>The pooled stone clearance rate was 77% in patients ≥80 and 65% in nonagenarians. When multiple ERCP sessions were employed, clearance rates increased to 84% in patients aged ≥80 and 82% in nonagenarians, compared with 61% and 38%, respectively, for single-session procedures. The pooled AEs rate was 8% in patients ≥80 and 6% in those ≥90, with ERCP-related mortality between 0% and 1%. Complete clearance was significantly lower in patients aged ≥80 versus those aged <80 (OR = 0.41; p = 0.003), and in patients aged ≥90 versus those aged <90 (OR = 0.30; p = 0.047), while cannulation success and AEs was similar. Additionally, elderly patients were more likely to receive general anesthesia (OR = 7.08, p < 0.001) and biliary stenting (OR = 2.78; p = 0.002), with permanent stents used more frequently (OR = 15.66, p < 0.001). Nonagenarians experienced higher cardiopulmonary risks (OR = 4.60; p = 0.042).</p><p><strong>Conclusion: </strong>ERCP is effective and safe for elderly patients, though age-related challenges necessitate tailored approaches. Staged procedures and age-adjusted sedation can mitigate risks. While permanent stenting offers palliative utility, long-term monitoring is essential to address late complications.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"718-730"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Projected Tumor Characteristics and Survival of Patients with Nonviral Hepatocellular Carcinoma in the USA.","authors":"Joanne Kimiko Liu, Nicholas Chien, Curtis Chong, Scott Barnett, Linda Henry, Esther M John, Ramsey Cheung, Mindie H Nguyen","doi":"10.1159/000546600","DOIUrl":"10.1159/000546600","url":null,"abstract":"<p><p><p>Introduction: Nonviral liver diseases, including alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), are increasing the burden of nonviral hepatocellular carcinoma (HCC) in the USA. We aimed to model and project the demographic and tumor characteristics and survival of individuals with nonviral HCC in the USA.</p><p><strong>Methods: </strong>We performed a cohort study using the linked Surveillance, Epidemiology, and End Results Program (SEER) and Medicare enrollment database (2000-2017). Of 78,431 adult Medicare beneficiaries with HCC, we excluded patients with a nonprimary liver tumor, HCC diagnosis before Medicare coverage started, and without a primary liver disease etiology of MASLD or ALD. We used linear regression to model changes in demographic and tumor characteristics and survival of patients with nonviral HCC and applied this model to describe future trends up to 2035.</p><p><strong>Results: </strong>In our cohort of 23,926 patients with nonviral HCC (18,266 with MASLD and 5,660 with ALD), the mean age at diagnosis between 2000 and 2017 was 73 years and 68-69% were male. Though we projected increasing trends for survival, both median (1.31 years [95% CI: 1.22-1.41] in 2035) and 5-year survival rates (22.0% [95% CI: 19.9-24.2] in 2027) are expected to remain low. We projected that by 2027, 1/3 of patients will be diagnosed with stage III or IV tumors, and by 2030, more than 1/3 of HCC diagnoses will be of multifocal and metastatic tumors.</p><p><strong>Conclusion: </strong>Focused efforts are needed to expand the use and effectiveness of HCC screening to improve the early detection and survival outcomes of HCC. </p>.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"541-554"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgement to Reviewers.","authors":"","doi":"10.1159/000549180","DOIUrl":"10.1159/000549180","url":null,"abstract":"","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"749-750"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145491288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}